The ENIGMA COVID-19 group is led by Drs. Carrie Esopenko (ce216@shp.rutgers.edu) and Lisa Wilde (Elisabeth.wilde@hsc.utah.edu).

There are several active projects within the COVID-19 group currently led by Dr. Maheen Adamson (madamson@stanford.edu). Dr. Maheen Mausoof Adamson is Clinical Research Senior Scientific Director for Headache Center of Excellence at Rehabilitation Services, VA Palo Alto and Clinical Associate Professor at Department of Neurosurgery, Stanford School of Medicine. Dr. Adamson’s expertise and interests span employing translational neuroscience methodologies for diagnostic and neuromodulation treatments (such as repetitive Transcranial Magnetic Stimulation (rTMS)) for frequent health problems in patients with Traumatic Brain Injury (TBI), psychiatric problems, and Alzheimer's disease. She has employed advanced structural and functional imaging modalities and biomarker assessments in Veteran, active military and civilian populations with these health problems. She has also focused on identifying gender differences in brain injury, particularly in the Veteran population. She currently serves as PI and Site-PI on numerous neuromodulation clinical trials and collaborates internationally for developing advanced diagnostic methods in neuroimaging, especially in underserved communities. In her position at VA Palo Alto, she is actively involved in translating research, such as non-invasive brain stimulation and other therapies, to clinical in-home use by patients using innovations such as virtual and augmented reality.